Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Revvity Inc (RVTY) vs Texas Instruments Incorporated (TXN) Price & Performance

Revvity IncTrade
Texas Instruments IncorporatedTrade

Price performance (Past 24H)

Key statistics

Revvity Inc vs Texas Instruments Incorporated — how do they compare? Revvity Inc trades at $117.6 (market cap $12.91B), while Texas Instruments Incorporated trades at $276.5 (market cap $256.84B). The key difference: Texas Instruments Incorporated is far larger — about 19.9× Revvity Inc's market cap, and Texas Instruments Incorporated pays the higher dividend (2.02%). Which is the better fit depends on your goals.

RVTYTXN
Market Cap
$12.91B$256.84B
Sector
TechnologyTechnology
52-Week High
$117.75$332.35
52-Week Low
$82.26$153.33
Enterprise Value
$15.23B$263.89B
Dividend Yield
0.24%2.02%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Revvity Inc

RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.

The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.

Texas Instruments Incorporated

Texas Instruments (TXN) trades at $280.44, down 1.97% on the day, with a bullish technical signal from moving averages. Recent earnings show beats in Q1 and Q2 2026, with Q3 expected at $2.37 EPS. The company maintains strong profitability with a 31.11% net margin and a 34.97% ROE, though valuation ratios like a P/E of 42.74 appear elevated. Positive sentiment is driven by AI data center demand and a smooth CFO transition announced in June 2026.

Outlook is cautiously optimistic with a consensus price target of $334.75, implying 19% upside, supported by AI growth and operational leverage. Risks include high debt-to-asset ratio of 40.61% and competitive pressures in semiconductors. Investors should weigh strong cash flow and dividend yield against valuation concerns for long-term holdings.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY

About Texas Instruments Incorporated

Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.

Read more on TXN